GleamWall
中文EN

SKYE Skye Bioscience, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1516551 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.5%
TTM EPS YoY126.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-220.3%
ROA-162.4%
ROIC (approx.)-557.6%
Asset turnover—

Leverage & solvency

Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.36x
Interest coverage-4,388.42x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$42.36M$18.70M
SG&A expense$15.80M$17.73M
Operating income-$58.16M-$30.19M
Interest expense$0$749,308
Pretax income-$55.92M-$26.56M
Income tax$5,400$10,071
Net income-$55.92M-$26.57M
EBITDA-$57.44M-$29.89M
EPS (basic)-1.41-0.73
EPS (diluted)-1.41-0.73
Weighted avg. shares (diluted)39.66M36.49M
Balance sheet
Cash & equivalents$5.88M$68.42M
Short-term investments$19.85M$0
Current assets$27.09M$70.83M
PP&E, net$898,930$1.43M
Total assets$28.31M$72.76M
Current liabilities$8.21M$4.34M
Total liabilities$8.29M$4.61M
Shareholders' equity$20.02M$68.15M
Shares outstanding4.17M30.97M
Cash flow statement
Operating cash flow-$43.06M-$25.24M
Capital expenditure$6,312$1.60M
Free cash flow-$43.07M-$26.84M
Investing cash flow-$19.50M-$245,615
Financing cash flow$29,571$83.56M
Depreciation & amortization$723,352$298,640
Stock-based compensation$7.77M$8.32M

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.